

Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A method of producing a colloidal preparation comprising cationic colloidal nanoparticles and an active agent comprising ~~the steps of~~,

- a) providing an active agent;
- b) providing empty cationic nanoparticles comprising a cationic component; and
- c) incubating said active agent of step a) with the empty cationic colloidal nanoparticles of step b) in an aqueous medium for a period of time sufficient to cause loading of said agent into said cationic nanoparticles in a self-assembly process,
~~wherein step c) is performed without further steps as a self assembly process wherein the active agent at least partially penetrates into a membrane.~~

Claim 2 (original): The method of claim 1, wherein said active agent is water soluble and/or comprises an anionic moiety and a moiety which can interact by amphiphilic interactions and wherein said active agent has a high partition coefficient into said nanoparticles in an aqueous solution.

Claim 3 (currently amended): The method of claim 1, wherein said active agent is present in an amount of about 0.1 mol% to less than about 100 mol%, ~~preferably from about 1 mol% to about 50 mol%, more preferably from about 3 mol% to about 30 mol% and most preferably from about 5 mol% to about 10 mol%~~ with respect to the amount of said cationic component of said cationic nanoparticles of step b).

Claim 4 (previously presented): The method of claim 1, wherein said active agent is selected from a camptothecin drug in the carboxylate form.

Claim 5 (original): The method of claim 4, wherein said camptothecin drug is selected from camptothecin, 10-OH-CPT or SN38.

Claim 6 (currently amended): The method of claims 4 or 5, wherein the lactone form of a camptothecin drug is present in said preparation in an amount of below about 10%, ~~preferably of below about 8%, more preferably of below about 6% and more preferably of below about 4%~~ with respect to the total amount of the carboxylate drug.

Claim 7 (previously presented): The method of claim 4, wherein said camptothecin drug can be present as an aqueous solution or a solid product.

Claim 8 (previously presented): The method of claim 1, wherein said cationic nanoparticles of step b) are selected from micelles, liposomes and nanocapsules.

Claim 9 (previously presented): The method of claim 1, wherein said empty cationic nanoparticles of step b) can be present as an aqueous dispersion or a solid product.

Claim 10 (currently amended): The method of claim 1, wherein said cationic nanoparticles of step b) comprise as cationic component cationic amphiphiles or polymers, ~~particularly cationic polyelectrolytes.~~

Claim 11 (currently amended): The method of claim 1, wherein said cationic nanoparticles of step b) comprise as cationic component cationic lipids, ~~particularly cationic lipids selected from DOTAP or DMTAP.~~

Claim 12 (currently amended): The method of claim 1, wherein said incubation time of step c) is between about 10 min and about 6 hours, ~~preferably between about 30 min and about 2 hours.~~

Claim 13 (currently amended): The method of claim 1, wherein said incubation temperature of step c) is between about 4°C and about 25°C, ~~preferably about 25°C.~~

Claim 14 (currently amended): The method of claim 1, wherein said preparation is obtained after c) and which is suitable for immediately, e. g. directly administering it to a subject

in need thereof.

Claim 15 (previously presented): The method of claim 1, wherein said colloidal preparation has a pH in the range of about 6 to about 8.

Claim 16-22 (canceled)

Claim 23 (new): The method of claim 1, wherein said active agent is present in an amount of about 1 mol% to about 50 mol% with respect to the amount of said cationic component of said cationic nanoparticles of step b).

Claim 24 (new): The method of claim 1, wherein said active agent is present in an amount of about 3 mol% to about 30 mol% with respect to the amount of said cationic component of said cationic nanoparticles of step b).

Claim 25 (new): The method of claim 1, wherein said active agent is present in an amount of about 5 mol% to about 10 mol% with respect to the amount of said cationic component of said cationic nanoparticles of step b).

Claim 26 (new): The method of claims 4 or 5, wherein the lactone form of a camptothecin drug is present in said preparation in an amount of below about 8% with respect to the total amount of the carboxylate drug.

Claim 27 (new): The method of claims 4 or 5, wherein the lactone form of a camptothecin drug is present in said preparation in an amount of below about 6% with respect to the total amount of the carboxylate drug.

Claim 28 (new): The method of claims 4 or 5, wherein the lactone form of a camptothecin drug is present in said preparation in an amount of below about 4% with respect to the total amount of the carboxylate drug.

Claim 29 (new): The method of claim 10, wherein said cationic nanoparticles of step b) comprise as cationic component cationic polyelectrolytes.

Claim 30 (new): The method of claim 11, wherein said cationic lipids are DOTAP or DMTAP.

Claim 31 (new): The method of claim 12, wherein said incubation time of step c) is between about 30 minutes and about 2 hours.

Claim 32 (new): The method of claim 13, wherein said incubation temperature of step c) is about 25° C.